Skip to main content
Top
Published in: Supportive Care in Cancer 6/2015

01-06-2015 | Original Article

Complementary and alternative medicine for cancer patients: results of the EPAAC survey on integrative oncology centres in Europe

Authors: Elio Rossi, Alessandra Vita, Sonia Baccetti, Mariella Di Stefano, Fabio Voller, Alberto Zanobini

Published in: Supportive Care in Cancer | Issue 6/2015

Login to get access

Abstract

Background

The Region of Tuscany Health Department was included as an associated member in WP7 “Healthcare” of the European Partnership for Action Against Cancer (EPAAC), initiated by the EU Commission in 2009.

Aims

The principal aim was to map centres across Europe prioritizing those that provide public health services and operating within the national health system in integrative oncology (IO).

Methods

A cross-sectional descriptive survey design was used to collect data. A questionnaire was elaborated concerning integrative oncology therapies to be administered to all the national health system oncology centres or hospitals in each European country. These institutes were identified by convenience sampling, searching on oncology websites and forums. The official websites of these structures were analysed to obtain more information about their activities and contacts.

Results

Information was received from 123 (52.1 %) out of the 236 centres contacted until 31 December 2013. Forty-seven out of 99 responding centres meeting inclusion criteria (47.5 %) provided integrative oncology treatments, 24 from Italy and 23 from other European countries. The number of patients seen per year was on average 301.2 ± 337. Among the centres providing these kinds of therapies, 33 (70.2 %) use fixed protocols and 35 (74.5 %) use systems for the evaluation of results. Thirty-two centres (68.1 %) had research in progress or carried out until the deadline of the survey. The complementary and alternative medicines (CAMs) more frequently provided to cancer patients were acupuncture 26 (55.3 %), homeopathy 19 (40.4 %), herbal medicine 18 (38.3 %) and traditional Chinese medicine 17 (36.2 %); anthroposophic medicine 10 (21.3 %); homotoxicology 6 (12.8 %); and other therapies 30 (63.8 %). Treatments are mainly directed to reduce adverse reactions to chemo-radiotherapy (23.9 %), in particular nausea and vomiting (13.4 %) and leucopenia (5 %). The CAMs were also used to reduce pain and fatigue (10.9 %), to reduce side effects of iatrogenic menopause (8.8 %) and to improve anxiety and depression (5.9 %), gastrointestinal disorders (5 %), sleep disturbances and neuropathy (3.8 %).

Conclusions

Mapping of the centres across Europe is an essential step in the process of creating a European network of centres, experts and professionals constantly engaged in the field of integrative oncology, in order to increase, share and disseminate the knowledge in this field and provide evidence-based practice.
Literature
1.
go back to reference Ernst E, Cassileth BR (1998) The prevalence of complementary/alternative medicine in cancer. A systematic review. Cancer 83:777–782CrossRefPubMed Ernst E, Cassileth BR (1998) The prevalence of complementary/alternative medicine in cancer. A systematic review. Cancer 83:777–782CrossRefPubMed
2.
go back to reference Horneber M, Bueschel G, Dennert G et al (2012) How many cancer patients use complementary and alternative medicine: a systematic review and meta-analysis. Integr Cancer Ther 11:187–203CrossRefPubMed Horneber M, Bueschel G, Dennert G et al (2012) How many cancer patients use complementary and alternative medicine: a systematic review and meta-analysis. Integr Cancer Ther 11:187–203CrossRefPubMed
3.
go back to reference Molassiotis A, Fernadez-Ortega P, Pud D et al (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–6CrossRefPubMed Molassiotis A, Fernadez-Ortega P, Pud D et al (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–6CrossRefPubMed
4.
go back to reference Sagar SM (2008) The integrative oncology supplement—a paradigm for both patient care and communication. Curr Oncol 15:166–7PubMedCentralPubMed Sagar SM (2008) The integrative oncology supplement—a paradigm for both patient care and communication. Curr Oncol 15:166–7PubMedCentralPubMed
5.
go back to reference Cassileth BR, Deng G, Vickers AJ et al (2005) Integrative oncology: complementary therapies in cancer care. BC Decker, Hamilton Ontario, Canada Cassileth BR, Deng G, Vickers AJ et al (2005) Integrative oncology: complementary therapies in cancer care. BC Decker, Hamilton Ontario, Canada
6.
go back to reference Sagar SM (2006) Integrative oncology in North America. J Soc Integr Oncol 4:27–39PubMed Sagar SM (2006) Integrative oncology in North America. J Soc Integr Oncol 4:27–39PubMed
7.
go back to reference Deng GE, Frenkel M, Cohen L, on behalf of the Society for Integrative Oncology et al (2009) Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol 7:85–120PubMed Deng GE, Frenkel M, Cohen L, on behalf of the Society for Integrative Oncology et al (2009) Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol 7:85–120PubMed
8.
go back to reference Gansler T, Kaw C, Crammer C, Smith T (2008) A population-based study of prevalence of complementary methods use by cancer survivors: a report from the American Cancer Society’s studies of cancer survivors. Cancer 113:1048–57CrossRefPubMed Gansler T, Kaw C, Crammer C, Smith T (2008) A population-based study of prevalence of complementary methods use by cancer survivors: a report from the American Cancer Society’s studies of cancer survivors. Cancer 113:1048–57CrossRefPubMed
9.
go back to reference Ernst E, White A (2000) The BBC survey of complementary medicine use in UK. Complement Ther Med 8:32–6CrossRefPubMed Ernst E, White A (2000) The BBC survey of complementary medicine use in UK. Complement Ther Med 8:32–6CrossRefPubMed
10.
go back to reference Scott JA, Kearney N, Hummerston S (2005) Use of complementary and alternative medicine in patients with cancer: a UK survey. Eur J Oncol Nurs 9:131–7CrossRefPubMed Scott JA, Kearney N, Hummerston S (2005) Use of complementary and alternative medicine in patients with cancer: a UK survey. Eur J Oncol Nurs 9:131–7CrossRefPubMed
11.
go back to reference Egan B, Gage H, Hood J et al (2012) Availability of complementary and alternative medicine for people with cancer in the British National Health Service: results of a national survey. Complement Ther Clin Pract 18:75–80CrossRefPubMed Egan B, Gage H, Hood J et al (2012) Availability of complementary and alternative medicine for people with cancer in the British National Health Service: results of a national survey. Complement Ther Clin Pract 18:75–80CrossRefPubMed
14.
go back to reference Johannessen H, von Bornemann HJ, Pasquarelli E et al (2008) Prevalence in the use of complementary medicine among cancer patients in Tuscany, Italy. Tumori 94:406–10PubMed Johannessen H, von Bornemann HJ, Pasquarelli E et al (2008) Prevalence in the use of complementary medicine among cancer patients in Tuscany, Italy. Tumori 94:406–10PubMed
15.
go back to reference Salomonsen LJ, Skovgaard L, La Cour S et al (2011) Use of complementary and alternative medicine at Norwegian and Danish hospitals. BMC Compl Alt Med 11:4CrossRef Salomonsen LJ, Skovgaard L, La Cour S et al (2011) Use of complementary and alternative medicine at Norwegian and Danish hospitals. BMC Compl Alt Med 11:4CrossRef
17.
go back to reference Boon H, Verhoef M, O’Hara D, Findlay B (2004) From parallel practice to integrative healthcare: a conceptual framework. BMC Health Services Research vol. 4, article 1 Boon H, Verhoef M, O’Hara D, Findlay B (2004) From parallel practice to integrative healthcare: a conceptual framework. BMC Health Services Research vol. 4, article 1
18.
go back to reference Ben-Arye E, Schiff E, Zollman C, Heusser P, Mountford P, Frenkel M, Bar-Sela G, Lavie O (2013) Integrating complementary medicine in supportive cancer care models across four continents. Med Oncol 30(2):511. doi:10.1007/s12032-013-0511-1 CrossRefPubMed Ben-Arye E, Schiff E, Zollman C, Heusser P, Mountford P, Frenkel M, Bar-Sela G, Lavie O (2013) Integrating complementary medicine in supportive cancer care models across four continents. Med Oncol 30(2):511. doi:10.​1007/​s12032-013-0511-1 CrossRefPubMed
19.
go back to reference Cramer H, Cohen L, Dobos G, Witt CM (2013) Integrative oncology: best of both worlds—theoretical, practical and research issues. Evid Based Complement Alternat Med 2013:383142PubMedCentralPubMed Cramer H, Cohen L, Dobos G, Witt CM (2013) Integrative oncology: best of both worlds—theoretical, practical and research issues. Evid Based Complement Alternat Med 2013:383142PubMedCentralPubMed
20.
go back to reference Mittring N, Pérard M, Witt CM (2013) Corporate culture assessments in integrative oncology: a qualitative case study of two integrative oncology centres. Evid Based Complement Alternat Med 2013:316950CrossRefPubMedCentralPubMed Mittring N, Pérard M, Witt CM (2013) Corporate culture assessments in integrative oncology: a qualitative case study of two integrative oncology centres. Evid Based Complement Alternat Med 2013:316950CrossRefPubMedCentralPubMed
Metadata
Title
Complementary and alternative medicine for cancer patients: results of the EPAAC survey on integrative oncology centres in Europe
Authors
Elio Rossi
Alessandra Vita
Sonia Baccetti
Mariella Di Stefano
Fabio Voller
Alberto Zanobini
Publication date
01-06-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 6/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2517-4

Other articles of this Issue 6/2015

Supportive Care in Cancer 6/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine